Heron Therapeutics (NASDAQ:HRTX) has been given a $27.00 price objective by equities research analysts at Oppenheimer in a report released on Thursday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s price target suggests a potential upside of 75.32% from the stock’s current price.

Several other analysts have also weighed in on the company. Mizuho reissued a “buy” rating and set a $28.00 price objective on shares of Heron Therapeutics in a report on Friday, December 8th. Cowen reissued a “buy” rating and set a $40.00 price objective on shares of Heron Therapeutics in a report on Wednesday, December 6th. ValuEngine raised Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, November 30th. Zacks Investment Research raised Heron Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Wednesday, November 22nd. Finally, Noble Financial reissued a “buy” rating on shares of Heron Therapeutics in a report on Sunday, November 12th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $28.73.

Shares of Heron Therapeutics (NASDAQ HRTX) traded down $0.30 during trading hours on Thursday, hitting $15.40. The stock had a trading volume of 837,598 shares, compared to its average volume of 840,324. Heron Therapeutics has a one year low of $12.21 and a one year high of $18.40. The company has a current ratio of 2.12, a quick ratio of 2.02 and a debt-to-equity ratio of 0.62.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. The company had revenue of $8.57 million for the quarter, compared to analyst estimates of $8.12 million. research analysts expect that Heron Therapeutics will post -3.43 EPS for the current year.

Several institutional investors have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC lifted its position in shares of Heron Therapeutics by 2.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock worth $470,000 after buying an additional 771 shares during the period. Schwab Charles Investment Management Inc. lifted its position in shares of Heron Therapeutics by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock worth $2,363,000 after buying an additional 1,026 shares during the period. Legal & General Group Plc lifted its position in shares of Heron Therapeutics by 13.9% during the 1st quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,098 shares during the period. HighTower Advisors LLC lifted its position in shares of Heron Therapeutics by 11.4% during the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after buying an additional 1,700 shares during the period. Finally, Tudor Investment Corp ET AL lifted its position in shares of Heron Therapeutics by 10.2% during the 2nd quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock worth $258,000 after buying an additional 1,724 shares during the period.

TRADEMARK VIOLATION WARNING: “Oppenheimer Analysts Give Heron Therapeutics (HRTX) a $27.00 Price Target” was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/14/oppenheimer-analysts-give-heron-therapeutics-hrtx-a-27-00-price-target.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.